Highlights Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 12/12/2025 GMT			After hours 19:14:24
83.32 ^EUR	-0.38%		83.31	-0.01%

02:27pm	European health regulator recommends approval for GSK's twice-yearly asthma drug	RE
11:00am	India, France seal treaty revamp giving Paris dividend relief, Delhi tax rights	RE

Highlights

India, France seal treaty revamp giving Paris dividend relief, Delhi tax rights	10:53am	RE
Sanofi Says China Approved 2 Rare Blood Disorder Therapies	12-11	MT
French and Benelux stocks-Factors to watch	12-11	RE
Sanofi Wins Chinese Approval for Blood Disorder Drugs Qfitlia, Cablivi	12-11	MT
Sanofi's Qfitlia and Cablivi approved in China	12-11	RE
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial	12-10	RE
US FDA launches fresh safety scrutiny of approved RSV therapies for infants	12-09	RE
U.S. FDA officials inform Merck, Sanofi and AstraZeneca RSV antibody therapies would receive fresh safety scrutiny - sources familiar with the situation	12-09	RE
Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	12-09	MT
Sanofi warns of Insulin Lispro pen shortage says EMA	12-08	RE
Sanofi completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.	12-04	CI
Sanofi Completes Vicebio Acquisition to Add Respiratory Vaccine Candidate	12-04	MT
Sanofi Closes on UK Biotechnology Company Vicebio	12-04	MT
Sanofi Completes Acquisition of Vicebio	12-04
Sanofi completes acquisition of Vicebio	12-04	RE
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-Driven Antibody Optimisation Programs	12-04	CI
Regeneron Pharmaceuticals, Inc. and Tessera Therapeutics, Inc. to Jointly Develop Tsra-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency	12-01	CI
Sanofi's Paris Premises Raided by French Authorities Amid Probe of Past Financing Arrangement	11-25	MT
Regeneron, Sanofi Say EU Approves Dupixent for Inflammatory Skin Disease	11-25	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria	11-25	CI
Sanofi, Regeneron's Chronic Spontaneous Urticaria Drug Gets Approved in Europe	11-25	MT
Sanofi, Regeneron's Dupixent approved in EU for chronic spontaneous urticaria	11-25	RE
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness	11-20	RE
Bristol Myers, Sanofi sued by Texas over Plavix	11-20	RE
CIBC Launches Additional European Canadian Depositary Receipts	11-20	MT